FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for EGFR-Mutated NSCLC

Spur Therapeutics Unveils SPR301: A Novel Gene Therapy for GBA1-Linked Parkinson’s Disease

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

Home
/
med-marvels
/
details

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

NextEdge Admin

04 Dec 2024

2 min 9 sec

M | O | C Cancer Care & Research Centre has successfully discharged its first patient treated with CAR-T cell therapy for Relapsed Refractory Diffuse Large B-cell Lymphoma (DLBCL), becoming one of India’s pioneering community cancer care institutions to offer this advanced treatment.

The patient, a 60-year-old male from Thane, had battled lymphoma for over three years, with three failed regimens, including immunotherapy. Admitted on November 5, 2024, he received CAR-T therapy facilitated in collaboration with ImmunoACT. The patient experienced no complications and was discharged in stable condition on November 24, 2024, achieving remission.

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a breakthrough that uses genetically modified T-cells from the patient to specifically target and destroy cancer cells. This revolutionary approach offers hope to patients with aggressive blood cancers who have exhausted conventional options.

Dr. Suraj Chiraniya, Hemato-Oncologist and BMT Specialist, highlighted the significance of this achievement: “For patients with relapsed and refractory lymphomas, CAR-T therapy opens new doors when conventional treatments fail.” His colleague, Dr. Ashray Kole, added, “This milestone underscores CAR-T therapy’s potential to transform oncology care in India.”

This success marks a new era for M | O | C, showcasing its commitment to bringing innovative, life-saving therapies to the forefront of community oncology care, offering renewed hope to patients and their families.